Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Pavan

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2022
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID studyMaria V Dieci, Giuseppe Azzarello, Vittorina Zagonel, et al.
Translational Lung Cancer Research|October 17, 2022
Comprehensive analysis of T cell receptor repertoire in patients with <i>KRAS</i> mutant non-small cell lung cancerYadong Wang, Ling Peng, Ming Zhao, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Clinical Medicine|February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World StudyAntonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2022
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID studyMaria V Dieci, Giuseppe Azzarello, Vittorina Zagonel, et al.
Translational Lung Cancer Research|October 17, 2022
Comprehensive analysis of T cell receptor repertoire in patients with <i>KRAS</i> mutant non-small cell lung cancerYadong Wang, Ling Peng, Ming Zhao, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Clinical Medicine|February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World StudyAntonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.
Pageof 4